During the past decade, Synexus Lancashire Clinical Research Centre conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 12 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 7 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Synexus Lancashire Clinical Research Centre" #1 sponsor was "Kowa Research Europe" with 6 trials, followed by "Pfizer" with 5 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Phathom Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Synexus Lancashire Clinical Research Centre" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "CoLucid Pharmaceuticals" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Synexus Lancashire Clinical Research Centre" are "Dyslipidemia" (5 trials), "Psoriasis" (3 trials), "Cardiovascular Disease" (2 trials), "Hypercholesterolemia" (2 trials) and "Hyperlipidemia" (2 trials). Many other conditions were trialed in "Synexus Lancashire Clinical Research Centre" in a lesser frequency.

Most popular intervention types in "Synexus Lancashire Clinical Research Centre" are "Drug" (22 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Pitavastatin" (6 trials), "Atorvastatin" (3 trials), "BMS-986165" (2 trials) and "Bococizumab (PF-04950615; RN316)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Synexus Lancashire Clinical Research Centre" are 22 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Synexus Lancashire Clinical Research Centre". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Synexus Lancashire Clinical Research Centre, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Synexus Lancashire Clinical Research Centre, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".